|
|
|
Volumn 18, Issue 2, 2014, Pages
|
|
Making it to manufacturing. The potential success of broadly neutralizing monoclonal antibodies for HIV prevention, treatment, and possibly even a cure could come at a cost.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
HUMAN IMMUNODEFICIENCY VIRUS VACCINE;
MONOCLONAL ANTIBODY;
NEUTRALIZING ANTIBODY;
ARTICLE;
BIOREACTOR;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
IMMUNOLOGY;
AIDS VACCINES;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, NEUTRALIZING;
BIOREACTORS;
HIV INFECTIONS;
HUMANS;
|
|
EID: 84907032367
PISSN: 18166253
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (4)
|
|
References (0)
|
